Publication date: Sep 04, 2024
During COVID-19 pandemic, cases of postvaccination infections and restored SARS-CoV-2 virus have increased after full vaccination, which might be contributed to by immune surveillance escape or virus rebound. Here, artificial linear 9-mer human leucocyte antigen (HLA)-restricted UC peptides were designed based on the well-conserved S2 region of the SARS-CoV-2 spike protein regardless of rapid mutation and glycosylation hindrance. The UC peptides were characterized for its effect on immune molecules and cells by HLA-tetramer refolding assay for HLA-binding ability, by HLA-tetramer specific T cell assay for engaged cytotoxic T lymphocytes (CTLs) involvement, by HLA-dextramer T cell assay for B cell activation, by intracellular cytokine release assay for polarization of immune response, Th1 or Th2. The specific lysis activity assay of T cells was performed for direct activation of cytotoxic T lymphocytes by UC peptides. Mice were immunized for immunogenicity of UC peptides in vivo and immunized sera was assay for complement cytotoxicity assay. Results appeared that through the engagement of UC peptides and immune molecules, HLA-I and II, that CTLs elicited cytotoxic activity by recognizing SARS-CoV-2 spike-bearing cells and preferably secreting Th1 cytokines. The UC peptides also showed immunogenicity and generated a specific antibody in mice by both intramuscular injection and oral delivery without adjuvant formulation. In conclusion, a T-cell vaccine could provide long-lasting protection against SARS-CoV-2 either during reinfection or during SARS-CoV-2 rebound. Due to its ability to eradicate SARS-CoV-2 virus-infected cells, a COVID-19 T-cell vaccine might provide a solution to lower COVID-19 severity and long COVID-19.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | cell |
disease | MESH | COVID-19 pandemic |
disease | MESH | infections |
disease | IDO | assay |
pathway | REACTOME | Release |
disease | IDO | immune response |
disease | MESH | reinfection |
disease | MESH | long COVID |
drug | DRUGBANK | Coenzyme M |
disease | MESH | syndrome |
disease | IDO | protein |
drug | DRUGBANK | Saquinavir |
disease | MESH | virus infection |
drug | DRUGBANK | Amino acids |
disease | MESH | histocompatibility |
disease | IDO | blood |
drug | DRUGBANK | Proline |
disease | IDO | production |
disease | MESH | death |
pathway | REACTOME | Digestion |
drug | DRUGBANK | Isoxaflutole |
disease | MESH | viral load |
disease | IDO | infection |
drug | DRUGBANK | Spinosad |
drug | DRUGBANK | Adenosine 5′-phosphosulfate |
drug | DRUGBANK | Biotin |
drug | DRUGBANK | Phosphate ion |
drug | DRUGBANK | Glycerin |
drug | DRUGBANK | Polyethylene glycol |
drug | DRUGBANK | Rasagiline |
disease | IDO | infectivity |
drug | DRUGBANK | Guanosine |
pathway | REACTOME | Influenza Infection |
disease | MESH | cancer |
disease | MESH | breakthrough infections |
disease | MESH | hepatitis |
disease | MESH | glioblastoma |
pathway | REACTOME | Reproduction |